DNA Probe-based Diagnostic Market Critical Analysis with Expert Opinion | Abbott Laboratories, BD, Thermo Fisher Scientific
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
DNA Probe-based Diagnostic Market Critical Analysis with Expert Opinion | Abbott Laboratories, BD, Thermo Fisher Scientific
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Published: May 18, 2021
SANTA CLARA, Calif., May 18, 2021 /PRNewswire/ CorVent Medical, a private medtech company focused on developing versatile, lifesaving ventilators for critical care, announced that it has received CE Mark approval and is ready to launch commercial use of its RESPOND-19™ Ventilator in Europe. The novel system is designed for easy-to-use, flexible expansion of critical care ventilation capacity to allow hospitals to improve treatment of critically ill patients suffering from acute respiratory distress syndrome (ARDS). Optimized for day-to-day clinical use and overflow ventilation needs, the system provides invasive and non-invasive respiratory support at a lower cost of ownership without the traditional requirements for costly service or maintenance plans. In support of the company s continued commercial growth, CorVent has appointed seasoned medtech financial executive, Travis Murphy, as Chief Financial Officer (CFO).